Literature DB >> 26422285

Neonatal BO Incompatibility Is Associated With a Positive Cord Blood Direct Antiglobulin Test in Infants of Black Ethnicity.

Bülent Özgönenel1, Geetika Kukreja, Barbara O'Malley, Martin H Bluth.   

Abstract

ABO hemolytic disease of the newborn occurs almost exclusively in infants of blood group A and B who are born to group O mothers. Positive Direct Antiglobulin Test (DAT) can identify those infants who are at risk of developing the ABO hemolytic disease. Earlier studies have suggested that BO incompatibility is associated with a positive DAT in black infants. In this study we sought to determine whether ABO incompatibility type could be associated with a higher rate of DAT positivity or clinical hemolytic disease. We reviewed the electronic medical records of all ABO-incompatible births over a 2-year period. There were 1537 ABO-incompatible births during the study period. DAT was more commonly positive among BO incompatible (21.5% in BO vs. 14.8% in AO, P=0.001) and black (18.8% in blacks vs. 10.8% in nonblacks, P=0.003) infants. DAT positivity was significantly associated with both severe hyperbilirubinemia (P=0.028) and hemolytic anemia (P<0.001). BO incompatibility was significantly associated with hemolytic anemia, but not severe hyperbilirubinemia, in the infants tested.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26422285     DOI: 10.1097/MPH.0000000000000426

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Predicting Significant Hyperbilirubinemia in ABO Incompatibility: Is Cord Direct Antiglobulin Test Useful?

Authors:  Sphurti Chowdhary; Usha Devi; Sethuraman Giridhar
Journal:  Indian J Hematol Blood Transfus       Date:  2022-01-25       Impact factor: 0.915

2.  Hemolysis due to Alpha-Hemolytic Enterococcus Urinary Infection: A Rare Cause of Early and Severe Unconjugated Hyperbilirubinemia in a Neonate.

Authors:  Birol Karabulut; Esin Alpagut Gafil
Journal:  J Pediatr Intensive Care       Date:  2020-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.